MARKET

JSPR

JSPR

Jasper Therapeutics Inc
NASDAQ
5.15
+0.35
+7.29%
After Hours: 5.16 +0.01 +0.19% 17:00 04/29 EDT
OPEN
4.790
PREV CLOSE
4.800
HIGH
5.20
LOW
4.780
VOLUME
164.66K
TURNOVER
--
52 WEEK HIGH
26.84
52 WEEK LOW
3.130
MARKET CAP
77.36M
P/E (TTM)
-1.0539
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at JSPR last week (0421-0425)?
Weekly Report · 1d ago
Weekly Report: what happened at JSPR last week (0414-0418)?
Weekly Report · 04/21 11:56
Weekly Report: what happened at JSPR last week (0407-0411)?
Weekly Report · 04/14 11:43
Weekly Report: what happened at JSPR last week (0331-0404)?
Weekly Report · 04/07 11:42
Weekly Report: what happened at JSPR last week (0324-0328)?
Weekly Report · 03/31 11:56
JASPER THERAPEUTICS INC FILES FOR COMMON STOCK OFFERING OF UP TO $100 MLN - SEC FILING
Reuters · 03/26 20:54
Weekly Report: what happened at JSPR last week (0317-0321)?
Weekly Report · 03/24 11:42
JASPER THERAPEUTICS INC - ON MAR 14, TERMINATED CANTOR SALES AGREEMENT DATED NOV 10, 2022
Reuters · 03/19 20:46
More
About JSPR
More
Jasper Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapeutics targeting mast cell-driven diseases, such as Chronic Spontaneous Urticaria (CSU) and Chronic Inducible Urticaria (CIndU), and Asthma. The Company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (c-Kit) receptor on mast and stem cells. Briquilimab is a targeted aglycosylated monoclonal antibody that blocks stem cell factor from binding to the cell-surface receptor c-Kit, also known as CD117, thereby inhibiting signaling through the receptor. The SCF/c-Kit pathway is a survival signal for mast cells. It is also developing briquilimab as a one-time conditioning therapy for severe combined immunodeficiency (SCID) patients undergoing a second stem cell transplant for which it is conducting a Phase 1/2 clinical trial.
Recently
Symbol
Price
%Change

Webull offers Jasper Therapeutics Inc stock information, including NASDAQ: JSPR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, JSPR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading JSPR stock methods without spending real money on the virtual paper trading platform.